News Release

Latest News

May 13, 2019: Kyorin Signed Memorandum of Understanding on Marketing Collaboration with respect to Chronic Cough Treatment
April 2, 2019: Release of Alcohol-Free Hand Sanitizer Noahtect® Pro
March 27, 2019: Conclusion of Agreement on OTC Drug Marketing Rights with DER UAW PHARMACEUTICAL CO., LTD.
March 27, 2019: Conclusion of Agreement with Monospharm Trade Co., Ltd. Concerning Marketing Rights for Generic Medicines
February 5, 2019: Summary of Consolidated Financial Results (For the Third Quarter Ended Dec 31, 2018) [Japanese Standard]
February 5, 2019: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2019 - Supplementary Information
February 5, 2019: The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
January 7, 2019: Impact on Kyorin's Financial Performance of MSD's Decision to Voluntarily Recall Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
December 27, 2018: Hebrew University to Collaborate with KYORIN Strategic partnership aims to develop respiratory drug therapies
November 20, 2018: Launch of "Beova® Tablets 50mg" for the Treatment of Overactive Bladder
November 5, 2018: Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2018) [Japanese Standard]
November 5, 2018: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2019
November 5, 2018: Notice Regarding the Cancellation of Treasury Stock
November 2, 2018: Revision of Consolidated Financial Forecasts
September 27, 2018: Notice on Results and Completion of Acquisition of Treasury Stock through Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3) and Change to Major Shareholder
September 26, 2018: Notice of Acquisition of Treasury Stock and Purchase of Treasury Stock by Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3)
September 21, 2018: Kyorin Receives Marketing Approval in Japan for｢Beova Tablets 50mg｣ for the Treatment of Overactive Bladder
August 6, 2018: (Corrections: Corrections of Numeric Data) On the Partial Correction of the Summary Accounts of the First Quarter of the Business Year Ending in March 2019 [Japanese Standard] (Consolidated)
August 1, 2018: KYORIN Pharmaceutical and FAES Farma Sign Agreement on Development and Distribution of Imidafenacin in Latin America
July 31, 2018: Summary of Consolidated Financial Results（July 31, 2018)
July 31, 2018: Supplementary information (July 31, 2018)
July 31, 2018: Changes in Capital Policy and Shareholder Return Policy
July 31, 2018: Revision of Dividend Forecast in Fiscal Year ended March 31, 2019
May 10, 2018: Summary of consolidated financial results (May 10, 2018)
May 10, 2018: Supplementary information (May 10, 2018)
May 10, 2018: MSD and Kyorin Sign Agreement to Acquires Exclusive Distribution Rights for Therapeutic Agent for Allergic Rhinitis, NASONEX® Nasal
March 29, 2018: Kyorin Pharmaceutical Sign a License Agreement for "SK-1404," a Therapeutic Agent for Nocturia Due to Nocturnal Polyuria
February 5, 2018: Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2017)［Japanese Standard］
February 5, 2018: Consolidated Financial Results (For the third Quarter Ended Dec 31,2017)- Supplementary Information
December 19, 2017: Consolidation of Group Production Functions (Absorption-type Demerger and Absorption-type Merger among the Wholly Owned Subsidiaries of the Company)
November 22, 2017: Notice on Production and Marketing License Agreement with Vietnamese Pharmaceutical Company
November 6, 2017: Supplementary information (Nov 6, 2017)
November 6, 2017: Summary of Consolidated Financial Results(For the Second Quarter Ended September 30, 2017)　[Japanese Standard]
September 28, 2017: Establishment of a Subsidiary
July 31, 2017: Summary of Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)［Japanese Standard］
July 31, 2017: Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)- Supplementary Information
May 11, 2017: Summary of Consolidated Financial Results
May 11, 2017: Consolidation of Group Production Functions
April 11, 2017: Kyorin acquired licenses from Merck & Co., Inc., Kenilworth, N.J., U.S.A. for Investigational Therapy for Overactive Bladder (Code:KRP-114V) in Asia
February 22, 2017: Change of Representative Director and President at ActivX Biosciences, Inc.
February 22, 2017: Establishment of a Representative Office in the Republic of Indonesia
February 3, 2017: Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2016)［Japanese Standard］
February 3, 2017: Revision of Consolidated Financial Forecasts
February 3, 2017: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2017
January 11, 2017: Conclusion of Agreement on Business Alliance for Sale of Hand-Sanitizers
December 28, 2016: Change in Consolidated Subsidiaries (Share Transfer)
November 18, 2016: Release of DESALEX Tablets 5mg for treatment of allergic diseases
November 7, 2016: Consolidated Financial Results (For the second Quarter Ended Sep 30,2016)- Supplementary Information
November 7, 2016: Summary of Consolidated Financial Results (For the second Quarter Ended Sep 30,2016)［Japanese Standard］
October 17, 2016: Release of Alcohol free hand-sanitizer Noahtect